These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12971248)

  • 1. Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer.
    Edwards SJ
    Semin Oncol Nurs; 2003 Aug; 19(3 Suppl 1):19-39. PubMed ID: 12971248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapeutic management of advanced ovarian cancer.
    Gordon AN; Butler J
    Semin Oncol Nurs; 2003 Aug; 19(3 Suppl 1):3-18. PubMed ID: 12971247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for newly diagnosed and relapsed advanced ovarian cancer.
    Rose PG
    Semin Oncol Nurs; 2003 Nov; 19(4 Suppl 2):25-35. PubMed ID: 14702918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychosocial management of patients with recurrent ovarian cancer: treating the whole patient to improve quality of life.
    Fitch MI
    Semin Oncol Nurs; 2003 Aug; 19(3 Suppl 1):40-53. PubMed ID: 12971249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum.
    Frey MK; Ellis AE; Koontz LM; Shyne S; Klingenberg B; Fields JC; Chern JY; Blank SV
    Gynecol Oncol; 2017 Aug; 146(2):386-391. PubMed ID: 28602549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cancer treatment: the benefit of patient telephone follow-up post-chemotherapy.
    Kelly DF; Faught WJ; Holmes LA
    Can Oncol Nurs J; 1999; 9(4):175-8. PubMed ID: 10786473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nursing perspectives on patient management during chronic therapy for relapsed ovarian cancer.
    Frazier SR
    Cancer Control; 2001; 8(6 Suppl 1):19-21. PubMed ID: 11910333
    [No Abstract]   [Full Text] [Related]  

  • 8. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stigma of hair loss after chemotherapy.
    Reid U
    Paediatr Nurs; 1997 Apr; 9(3):16-8. PubMed ID: 9306861
    [No Abstract]   [Full Text] [Related]  

  • 10. Centering prayer for women receiving chemotherapy for recurrent ovarian cancer: a pilot study.
    Johnson ME; Dose AM; Pipe TB; Petersen WO; Huschka M; Gallenberg MM; Peethambaram P; Sloan J; Frost MH
    Oncol Nurs Forum; 2009 Jul; 36(4):421-8. PubMed ID: 19581232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scalp cooling: management option for chemotherapy-induced alopecia.
    Roe H
    Br J Nurs; 2014 Sep 11-24; 23(16):S4, S6, S8 passim. PubMed ID: 25203854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian cancer: a nursing overview.
    Zimny ME
    Oncology (Williston Park); 1991 Aug; 5(8):147-53; discussion 154. PubMed ID: 1834149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The experience of chemotherapy-induced alopecia for Australian women with ovarian cancer.
    Jayde V; Boughton M; Blomfield P
    Eur J Cancer Care (Engl); 2013 Jul; 22(4):503-12. PubMed ID: 23528018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial.
    Nangia J; Wang T; Osborne C; Niravath P; Otte K; Papish S; Holmes F; Abraham J; Lacouture M; Courtright J; Paxman R; Rude M; Hilsenbeck S; Osborne CK; Rimawi M
    JAMA; 2017 Feb; 317(6):596-605. PubMed ID: 28196254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient perceptions of symptoms and concerns during cancer chemotherapy: 'affects my family' is the most important.
    Sasaki H; Tamura K; Naito Y; Ogata K; Mogi A; Tanaka T; Ikari Y; Masaki M; Nakashima Y; Takamatsu Y
    Int J Clin Oncol; 2017 Aug; 22(4):793-800. PubMed ID: 28386794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis.
    Donovan HS; Hagan TL; Campbell GB; Boisen MM; Rosenblum LM; Edwards RP; Bovbjerg DH; Horn CC
    Support Care Cancer; 2016 Jun; 24(6):2635-42. PubMed ID: 26746209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients.
    Kayl AE; Meyers CA
    Curr Opin Obstet Gynecol; 2006 Feb; 18(1):24-8. PubMed ID: 16493256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptom clustering and quality of life in patients with ovarian cancer undergoing chemotherapy.
    Nho JH; Reul Kim S; Nam JH
    Eur J Oncol Nurs; 2017 Oct; 30():8-14. PubMed ID: 29031318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of side effects in patients with recurrent ovarian cancer.
    Larrison EH
    Semin Oncol; 1999 Feb; 26(1 Suppl 1):15-31. PubMed ID: 10071970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.